US Stocks Move | Novo Nordisk continues to rise over 2% pre-market after five consecutive gains; CICC rates it "Outperform"

格隆汇2026/01/09 09:19

Show original

By:格隆汇

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Glonghui January 9th｜Novo Nordisk (NVO.US) continues to rise over 2% in pre-market trading, having previously recorded five consecutive days of gains. According to reports, CICC has given Novo Nordisk an “Outperform” rating with a target price of $73.50. The company is a global leader in metabolic diseases, with semaglutide driving growth in the GLP-1 market. The market size CAGR is expected to reach 23% from 2024 to 2030. The depth of the company’s pipeline supports future competition, with CagriSema and Amycretin expected to be launched in 2027/28, promoting an “alternating leadership” pattern. Strategic transformation into a comprehensive chronic disease platform is expected to enhance valuation premium potential.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Wall Street analysts generally believe that a potential acquisition could strengthen Marvell Technology's competitiveness in the field of AI optical communications. However, Lumentum's market value of up to approximately $83 billion, along with concerns about equity dilution, margin pressure, and business integration risks that the deal could bring, have also raised concerns in the market.

智通财经•2026/10/29 16:11

Updated Version 3 - Merck Raises Revenue Forecast for the Next Decade Due to Optimism About New Drug Prospects

路透社•2026/10/29 15:56

Updated Version 4 - Revisited Draft - Amid Artificial Intelligence Spending Boom, Investors Redraw Battle Lines, Cash is King

路透社•2026/10/29 15:38

Updated Version 2 - Correction - Bristol Myers Squibb Raises 2026 Revenue Forecast, Lowers Earnings Per Share Outlook Due to Provision for Expenses

路透社•2026/10/29 14:43